Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

Investors may be wary of CONCORDBIO as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 6.16800
forwardPE 34.42725
debtToEquity 0.16400
earningsGrowth 0.47800
revenueGrowth 0.34800
grossMargins 0.65191
operatingMargins 0.40896
trailingEps 35.60000
forwardEps 0.00000

CONCORDBIO's current ratio being 6.168 shows it has more than enough assets to cover its short-term debts. The company's liquidity position is strong, with ample cash reserves available to meet its immediate financial obligations without strain.
CONCORDBIO's positive earnings and revenue growth suggest the company is on a path to business expansion. This upward trend signals strong financial health, indicating that CONCORDBIO is well-positioned for sustained growth in both profits and revenue.
Positive gross and operating margins for CONCORDBIO demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

Over time, Concord Biotech Limited's price projections have been revised higher, signaling growing confidence in the company's future. This upward trend suggests analysts anticipate strong performance and increased market value for Concord Biotech Limited.

Insider Transactions:

Insider Transactions for CONCORDBIO
Insider Transactions for CONCORDBIO


CONCORDBIO had 2 sell transactions, while the market price was at 1583.050048828125 per share.During the period under consideration, no sell transactions took place.CONCORDBIO has seen more buys than sells at its current price levels, which may suggest optimism among investors. This buying trend could indicate that the market expects a favorable performance for the stock in the near future.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


Recent analysis shows a strong buy bias for CONCORDBIO, encouraging investors to view it as a solid investment option. The positive sentiment surrounding CONCORDBIO suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.